Practice · Europe ⟶ China

China is a sequencing problem before it is a market problem.

Regulatory approval does not guarantee access. Tier-1 traction does not guarantee national scale. The wrong distributor signed early can cost two years. We work in the order the market allows.

Where entries go wrong

Four failures we see repeatedly

  • Entering with the wrong product mix, because the study was done from a desk in Europe.
  • Letting the distributor control brand, pricing and registration — and discovering it two years later.
  • Treating regulatory approval as the finish line rather than the starting line of access.
  • Confusing Tier-1 city success with national scalability.

These mistakes are expensive and, within eighteen to twenty-four months, usually irreversible.

The eight gates

China market entry, step by step

Every one of these requires a different network and a different competence. Neither domestic nor foreign companies hold all eight.

1 IP Trademark,patent 2 Registration NMPA strategy,trial waiver 3 Clinical trial Local execution,case files 4 Importation Route andpartners 5 Distribution Identify, qualify,manage 6 Market access Pricing andreimbursement 7 Promotion Hire, train,manage 8 Feedback Pharmacovigilance,market data where entries most often fail Start Revenue
Each gate demands a different network and a different competence — which is why neither foreign nor domestic companies cover all eight alone.

The eight gates, in detail

What each gate decides

GateWhat it decides
1 · Intellectual propertyTrademark, copyright and patent protection, before anything is shown.
2 · RegistrationRegulatory strategy and, where possible, a clinical-trial waiver.
3 · Clinical trialLocal planning, execution and case organisation for the regulatory path.
4 · ImportationA clear importation route and the partners it requires.
5 · DistributionIdentifying, qualifying, contracting and then managing distributors.
6 · Market accessPricing and reimbursement strategy, national and provincial.
7 · PromotionBuilding the commercial and medical network — hire, train, manage.
8 · Continuous feedbackPharmacovigilance and market data: collect, analyse, report.

How we engage

Three levels, combinable

Level 1

Initial research

Field interviews and strategic market studies. Persona identification, regulatory pathway, competition, and a plan you can act on.

Level 2

Part-time management

We run the operation with you: business development, distributor negotiation, organisation build-up, fundraising and licensing.

Level 3

Part-time expertise

Senior challenge on strategy, regulatory and commercial execution — partners with fifteen years or more, on the days you need them.

Consultants hold at least two years of experience, senior consultants five, partners fifteen. You buy the seniority the question deserves — not a fixed team.